255 related articles for article (PubMed ID: 33373114)
1. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
[TBL] [Abstract][Full Text] [Related]
2. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
3. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
[TBL] [Abstract][Full Text] [Related]
4. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
[TBL] [Abstract][Full Text] [Related]
5. Can we stop nucleoside analogues before HBsAg loss?
Papatheodoridi M; Papatheodoridis G
J Viral Hepat; 2019 Aug; 26(8):936-941. PubMed ID: 30803099
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
Chen H; Ding X; Liao G; Xia M; Ren Z; Fan R; Peng J
J Viral Hepat; 2021 Aug; 28(8):1121-1129. PubMed ID: 33899998
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
8. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
[TBL] [Abstract][Full Text] [Related]
9. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
10. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
[TBL] [Abstract][Full Text] [Related]
11. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
Hall SAL; Burns GS; Anagnostou D; Vogrin S; Sundararajan V; Ratnam D; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus P; Sinclair M; Meredith C; Matthews G; Revill PA; Jackson K; Littlejohn M; Bowden DS; Locarnini SA; Visvanathan K; Thompson AJ
Aliment Pharmacol Ther; 2022 Jul; 56(2):310-320. PubMed ID: 35521992
[TBL] [Abstract][Full Text] [Related]
12. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
[TBL] [Abstract][Full Text] [Related]
13. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.
Yao CC; Hung CH; Hu TH; Lu SN; Wang JH; Lee CM; Chen CH
Sci Rep; 2017 May; 7(1):1839. PubMed ID: 28500322
[TBL] [Abstract][Full Text] [Related]
14. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Manolakopoulos S; Su TH; Siakavellas S; Liu CJ; Kourikou A; Yang HC; Kao JH
Hepatology; 2018 Aug; 68(2):415-424. PubMed ID: 28859219
[TBL] [Abstract][Full Text] [Related]
15. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
[TBL] [Abstract][Full Text] [Related]
16. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
17. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
[TBL] [Abstract][Full Text] [Related]
18. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridi M; Hadziyannis E; Berby F; Zachou K; Testoni B; Rigopoulou E; Gatselis NK; Lyberopoulou A; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Papatheodoridis GV
J Viral Hepat; 2020 Feb; 27(2):118-126. PubMed ID: 31562748
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
20. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
